Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.03

Summit Therapeutics (NASDAQ: SMMT) reported Q3 EPS of (GBP0.03).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Exclusive: Axe Compute CEO says prepayments cover about a third of $3bn build cost
• HawkEye 360 lock-up ends early, shares eligible Sept. 2